Stimulation of p53 Transactivation Ability by Nicastrin in Mouse Fibroblasts

References

1. J. Hardy and D. J. Selkoe, “The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics,” Science, vol. 297, no. 5580, pp. 353–356, 2002.
2. M. S. Wolfe, “The $\gamma$-secretase complex: membrane-embedded proteolytic ensemble,” Biochemistry, vol. 45, no. 26, pp. 7931–7939, 2006.
3. N. Takasugi, T. Tomita, I. Hayashi, et al., “The role of presenilin cofactors in the $\gamma$-secratase complex,” Nature, vol. 422, no. 6930, pp. 438–441, 2003.
4. W. K. Taylor, M. J. LaVoie, B. L. Ostaszewski, W. Ye, M. S. Wolfe, and D. J. Selkoe, “$\gamma$-secretase is a membrane protein complex comprised of presenilin, nicastrin, aph-1, and pen-2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 11, pp. 6382–6387, 2003.
5. M. Niimura, N. Isoo, N. Takasugi, et al., “Aph-1 contributes to the stabilization and trafficking of the $\gamma$-secretase complex through mechanisms involving intermolecular and intramolecular interactions,” The Journal of Biological Chemistry, vol. 280, no. 13, pp. 12967–12975, 2005.
6. N. Isoo, C. Sato, H. Miyashita, et al., “$\text{A}\beta 42$ overproduction associated with structural changes in the catalytic pore of $\gamma$-secretase: common effects of Pen-2 N-terminal elongation and fenofibrate,” The Journal of Biological Chemistry, vol. 282, no. 17, pp. 12388–12396, 2007.
7. S. Shah, S. F. Lee, K. Tabuchi, et al., “Nicastrin functions as a $\gamma$-secretase-substrate receptor,” Cell, vol. 122, pp. 435–447, 2005.
8. B. De Strooper, P. Saftig, K. Craessaerts, et al., “Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein,” Nature, vol. 391, no. 6665, pp. 387–390, 1998.
9. B. De Strooper, W. Annaert, P. Cupers, et al., “A presenilin-1-dependent $\gamma$-secretase-like protease mediates release of notch intracellular domain,” Nature, vol. 398, no. 6727, pp. 518–522, 1999.
10. R. Kopan and M. X. Ilagan, “Gamma-secretase: proteasome of the membrane?,” Nature Reviews Molecular Cell Biology, vol. 5, pp. 499–504, 2004.
11. D. P. Lane and L. V. Crawford, “T antigen is bound to a host protein in SV40 transformed cells,” Nature, vol. 278, no. 5701, pp. 261–263, 1979.
12. D. I. Linzer and A. J. Levine, “Characterization of a 54 K dalton cellular SV40 tumor antigen present in SV40 transformed cells and uninfected embryonal carcinoma cells,” Cell, vol. 17, no. 1, pp. 43–52, 1979.
13. A. Yagi, Y. Hasegawa, H. Xiao, et al., “GADD34 induces p53 phosphorylation and p21/WAF1 transcription,” Journal of Cellular Biochemistry, vol. 90, no. 6, pp. 1242–1249, 2003.
14. H. Xiang, Y. Kinoshita, C. M. Knudson, S. J. Korsmeyer, P. A. Schwartzkroin, and R. S. Morrison, “Bax involvement in p53-mediated neuronal cell death,” Journal of Neuroscience, vol. 18, no. 4, pp. 1363–1373, 1998.
15. E. Oda, R. Ohki, H. Murasawa, et al., “Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis,” Science, vol. 288, no. 5468, pp. 1053–1058, 2000.
16. K. Nakano and K. H. Vousden, “PUMA, a novel proapoptotic gene, is induced by p53,” Molecular Cell, vol. 7, no. 3, pp. 683–694, 2001.
17. Y. Kitamura, S. Shimohama, W. Kamoshima, Y. Matsuoka, Y. Nomura, and T. Taniguchi, “Changes of p53 in the brains of patients with Alzheimer's disease,” Biochemical and Biophysical Research Communications, vol. 232, no. 2, pp. 418–421, 1997.
18. Y. Ohyagi, H. Asahara, D.-H. Chui, et al., “Intracellular $\text{A}\beta 42$ activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease,” The FASEB Journal, vol. 19, no. 2, pp. 255–257, 2005.
19. S. Tomita, Y. Kirino, and T. Suzuki, “Cleavage of Alzheimer's amyloid precursor protein (APP) by secretases occurs after O-glycosylation of APP in the protein secretory pathway. Identification of intracellular compartments in which APP cleavage occurs without using toxic agents that interfere with protein metabolism,” The Journal of Biological Chemistry, vol. 273, no. 11, pp. 6277–6284, 1998.
20. S. J. Baker, S. Markowitz, E. R. Fearon, J. K. V. Willson, and B. Vogelstein, “Suppression of human colorectal carcinoma cell growth by wild-type p53,” Science, vol. 249, no. 4971, pp. 912–915, 1990.
21. W. S. El-Deiry, S. E. Kern, J. A. Pietenpol, K. W. Kinzler, and B. Vogelstein, “Definition of a consensus binding site for p53,” Nature Genetics, vol. 1, no. 1, pp. 45–49, 1992.
22. T. Mizutani, Y. Taniguchi, T. Aoki, N. Hashimoto, and T. Honjo, “Conservation of the biochemical mechanisms of signal transduction among mammalian notch family members,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 16, pp. 9026–9031, 2001.
23. S. Minoguchi, Y. Taniguchi, H. Kato, et al., “RBP-L, a transcription factor related to RBP-J$\kappa$,” Molecular and Cellular Biology, vol. 17, no. 5, pp. 2679–2687, 1997.
24. P. Jiang, W. Du, K. Heese, and M. Wu, “The bad guy cooperates with good cop p53: bad is transcriptionally up-regulated by p53 and forms a bad/p53 complex at the mitochondria to induce apoptosis,” Molecular and Cellular Biology, vol. 26, no. 23, pp. 9071–9082, 2006.
25. P. L. Mellon, C. H. Clegg, L. A. Correll, and G. S. McKnight, “Regulation of transcription by cyclic AMP-dependent protein kinase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 13, pp. 4887–4891, 1989.
26. H. F. Dovey, V. John, J. P. Anderson, et al., “Functional $\gamma$-secretase inhibitors reduce $\beta$-amyloid peptide levels in brain,” Journal of Neurochemistry, vol. 76, pp. 173–181, 2001.
27. Y.-M. Li, M. Xu, M.-T. Lai, et al., “Photoactivated $\gamma$-secretase inhibitors directed to the active site covalently label presenilin 1,” Nature, vol. 405, no. 6787, pp. 689–694, 2000.
28. T. Sekiya, M. Fushimi, H. Hori, S. Hirohashi, S. Nishimura, and T. Sugimura, “Molecular cloning and the total nucleotide sequence of the human c-Ha-ras-1 gene activated in a melanoma from a Japanese patient,” Proceedings of the National Academy of Sciences of the United States of America, vol. 81, no. 15 I, pp. 4771–4775, 1984.
29. T. Hiwasa, M. Nakata, M. Nakata, et al., “Regulation of transformed state by calpastatin via PKC$\epsilon$ in NIH3T3 mouse fibroblasts,” Biochemical and Biophysical Research Communications, vol. 290, no. 1, pp. 510–517, 2002.
30. T.-L. Liu, H. Shimada, T. Ochiai, et al., “Enhancement of chemosensitivity toward peplomycin by calpastatin-stabilized NF-$\kappa$B p65 in esophageal carcinoma cells: possible involvement of Fas/Fas-L synergism,” Apoptosis, vol. 11, no. 6, pp. 1025–1037, 2006.
31. T. Hiwasa, Y. Arase, K. Kikuno, et al., “Increase in ultraviolet sensitivity by overexpression of calpastatin in ultraviolet-resistant ${\text{UV}}^{\text{r}}$-1 cells derived from ultraviolet-sensitive human RSa cells,” Cell Death and Differentiation, vol. 7, no. 6, pp. 531–537, 2000.
32. G. Yu, M. Nishimura, S. Arawaka, et al., “Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and $\beta$-APP processing,” Nature, vol. 407, pp. 48–54, 2000.
33. T. Hiwasa, H. Shimada, T. Sakaida, et al., “Drug-sensitivity pattern analysis for study of functional relationship between gene products,” FEBS Letters, vol. 552, no. 2-3, pp. 177–183, 2003.
34. C. Alves da Costa, C. Sunyach, R. Pardossi-Piquard, et al., “Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease,” The Journal of Neuroscience, vol. 26, no. 23, pp. 6377–6385, 2006.
35. J. Dunys, T. Kawarai, and J. Sevalle, “p53-dependent Aph-1 and Pen-2 anti-apoptotic phenotype requires the integrity of the $\gamma$-secretase complex but is independent of its activity,” The Journal of Biological Chemistry, vol. 282, no. 14, pp. 10516–10525, 2007.
36. W. A. Campbell, H. Yang, H. Zetterberg, et al., “Zebrafish lacking Alzheimer presenilin enhancer 2 (Pen-2) demonstrate excessive p53-dependent apoptosis and neuronal loss,” Journal of Neurochemistry, vol. 96, no. 5, pp. 1423–1440, 2006.
37. R. Pardossi-Piquard, J. Dunys, E. Giaime, et al., “P53-dependent control of cell death by nicastrin: lack of requirement for presenilin-dependent $\gamma$-secretase complex,” Journal of Neurochemistry, vol. 109, no. 1, pp. 225–237, 2009.
38. M. E. Boulton, J. Cai, and M. B. Grant, “$\gamma$-secretase: a multifaceted regulator of angiogenesis,” Journal of Cellular and Molecular Medicine, vol. 12, no. 3, pp. 781–795, 2008.
39. P. Marambaud and N. K. Robakis, “Genetic and molecular aspects of Alzheimer's disease shed light on new mechanisms of transcriptional regulation,” Genes, Brain and Behavior, vol. 4, no. 3, pp. 134–146, 2005.
40. S. H. Kim, A. C. Nairn, N. Cairns, and G. Lubec, “Decreased levels of ARPP-19 and PKA in brains of Down syndrome and Alzheimer's disease,” Journal of Neural Transmission. Supplement, no. 61, pp. 263–272, 2001.
41. F. G. De Felice, A. P. Wasilewska-Sampaio, A. C. A. P. Barbosa, F. C. A. Gomes, W. L. Klein, and S. T. Ferreira, “Cyclic AMP enhancers and $\text{A}\beta$ oligomerization blockers as potential therapeutic agents in Alzheimer's disease,” Current Alzheimer Research, vol. 4, no. 3, pp. 263–271, 2007.